New Augmented Reality Surgical Platform Receives FDA Approval

By HospiMedica International staff writers
Posted on 22 Jun 2019

A new augmented reality (AR) technology platform for surgical applications has received 510(k) clearance for clinical use in the operating room by the US Food and Drug Administration (FDA).

The enterprise SurgicalAR platform developed by medical technology company Medivis (New York, NY, USA) integrates the latest advancements in AR, artificial intelligence (AI), and computer vision to advance surgical visualization, thereby reducing surgical complications and improving patient outcomes while lowering costs for healthcare systems.

Image: The SurgicalAR platform is a data integration tool that gathers the most relevant patient information and presents it as a 3D model. The rendered 3D model of a patient is mapped back onto the patient, which saves the usual chore of gathering data from all around in order to plan for surgery (Photo courtesy of Medivis).

Medivis, which harnesses AR and AI to advance surgical visualization, will commence the immediate commercialization of the enterprise SurgicalAR platform in the US.

"Holographic visualization is the final frontier of surgical imaging and navigation," said Dr. Osamah Choudhry, neurosurgeon & CEO of Medivis. "The surgical world continues to primarily rely on two-dimensional imaging technology to understand and operate on incredibly complex patient pathology."

"Medivis introduces advancements in holographic visualization and navigation to fundamentally advance surgical intervention, and revolutionize how surgeons safely operate on their patients," said Dr. Christopher Morley, radiologist & President of Medivis. "Achieving this milestone accelerates our mission to improve surgical precision and safety by allowing surgeons to see the invisible."

Related Links:
Medivis